Digestive System Nutritional, Metabolic, Endocrine
Conditions
Interventions
Placebo
Vitamin E and L Carnitine supplementation
Sponsors
Faculty of Medicine AlAzhar University Assiut
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged above 18 years. Patients diagnosed with non-alcoholic fatty liver disease / metabolic dysfunction-associated steatotic liver disease. Hepatic steatosis detected by imaging techniques. Presence of overweight or obesity defined as BMI > 25 kg/m², or type 2 diabetes mellitus, or at least two metabolic dysregulation criteria in non-obese/non-diabetic individuals. Metabolic dysregulation criteria include increased waist circumference, pre-diabetes, blood pressure >130/85 mmHg or treatment, triglycerides >150 mg/dL or lipid-lowering treatment, low HDL cholesterol, HOMA-IR >2.5, or high-sensitivity CRP >2 mg/L. Patients willing to participate and provide informed consent.
Exclusion criteria
Exclusion criteria: Patients aged less than 18 years. Patients with liver diseases other than NAFLD/MASLD, such as viral hepatitis, Wilson disease, or autoimmune hepatitis. Patients recently exposed to hepatotoxic drugs within the last 6 months. Patients who refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in hepatic steatosis and liver fibrosis after treatment, assessed by controlled attenuation parameter (CAP score) and liver stiffness measurement using transient elastography/FibroScan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in liver biochemical tests including ALT, AST, total and direct bilirubin, serum albumin, total proteins, GGT, and ALP. | — |
Countries
Egypt
Contacts
Public ContactAbdulaziz Sabra ElSayed
Resident doctor of hepatoloGastroenterology Al Azhar University hospital Assiut
Outcome results
None listed